|
CRA-024781 is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. It is being developed by Celera Genomics for the treatment of cancer and currently under Phase I of clinical trail.
|
